Mustonen, A., Leijala, J., Aronranta, J., Lassila, A., Aalto, M., & Koskimäki, J. (2021). Withdrawal from Long-Term Use of Unusually High-Dose Oxazepam. Case Reports in Psychiatry, 2021, 1–4. https://doi.org/10.1155/2021/2140723
Withdrawal from long-term use of unusually high-dose oxazepam
|Author:||Mustonen, Antti1,2,3; Leijala, Juhani3; Aronranta, Johanna3;|
1Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland
2Center for Life Course Health Research, University of Oulu, Oulu, Finland
3Department of Psychiatry, Central Hospital of Southern Ostrobothnia, Hanneksenrinne 7, FI-60220 Seinäjoki, Finland
4Neuroscience Center, HiLIFE, University of Helsinki, Box 63, 00014 Helsinki, Finland
5Division of Clinical Neurosciences, Department of Neurosurgery, Turku University Hospital and University of Turku, P.O. Box 52, Hämeentie 11, FI-20521 Turku, Finland
|Online Access:||PDF Full Text (PDF, 0.4 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe2022030221497
|Publish Date:|| 2022-03-02
Benzodiazepine (BZD) misuse is a worldwide problem that healthcare professionals encounter in daily practice. High-dose BZD withdrawal is usually a long process that may require referral to an inpatient rehabilitation unit. Relapses after withdrawal are common. BZD withdrawal can cause complications including seizures, suicidal behavior, anxiety, and depression. Guidelines describe tapering protocols for modest doses; however, protocols for exceptionally high-dose BZD withdrawal are not well described. Herein, we describe a BZD tapering protocol for a patient with daily use of high-dose (1800 mg) oxazepam (OXP). The BZD tapering was administered in an inpatient psychiatric hospital, and the outcome was evaluated monthly after discharge for three months. This report describes a unique case of high-dose OXP withdrawal and also outlines an optional protocol to apply when clinicians encounter these unusual cases.
Case reports in psychiatry
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
3124 Neurology and psychiatry
AM has previously received funding from the Finnish Foundation for Alcohol Studies, Emil Aaltonen Foundation, Juho Vainio Foundation, Olvi Foundation, and the Finnish Cultural Foundation. JK has received funding from Sigrid Juselius Foundation, the Finnish Medical Foundation, and Maire Taponen Foundation.
Copyright © 2021 Antti Mustonen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.